What question did this study set out to answer?

To assess survival, relapse, and toxicity outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with T-cell acute lymphoblastic leukemia in second complete remission.

August 29, 2015Biology of Blood and Marrow TransplantationOpen Access

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

View Full Paper

Ask AI

Bookmark

Authors

MBMichael J. Burke MVMichael R. Verneris JRJennifer Le Rademacher

Discussion

Member takes

Overview

Registry study finds 48% three-year survival following hematopoietic cell transplantation in pediatric relapsed T-cell leukemia, suggesting durable efficacy after second remission.

Key Points

To assess survival, relapse, and toxicity outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with T-cell acute lymphoblastic leukemia in second complete remission.
Retrospective registry analysis of 229 pediatric patients (median age 10 years, range 2 to 18) with T-ALL in CR2 who underwent myeloablative allogeneic HCT between 2000 and 2011, reported to the CIBMTR.
Donor graft sources included matched sibling bone marrow (38%), unrelated bone marrow or peripheral blood (36%), and umbilical cord blood (26%).
Three-year overall survival was 48% (95% CI, 41% to 55%), three-year disease-free survival was 46% (95% CI, 39% to 52%), and the three-year relapse rate was 30% (95% CI, 24% to 37%).
Day-100 transplant-related mortality was 13% (95% CI, 9% to 18%), with grades II to IV acute graft-versus-host disease occurring in 35% (95% CI, 27% to 45%) and chronic GVHD in 26% (95% CI, 20% to 33%).
Prior bone marrow relapse, with or without concurrent extramedullary disease, significantly increased the risk of post-HCT relapse compared with isolated extramedullary relapse (HR, 3.94; P = .005).

Cite This Study

Burke et al. (2015) studied this question.

synapsesocial.com/papers/6a70a4f2a528af2d65c3a7f7 https://doi.org/10.1016/j.bbmt.2015.08.023

View Full Paper

Ask AI

Bookmark

August 29, 2015Biology of Blood and Marrow TransplantationOpen Access

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

View Full Paper

Ask AI

Bookmark

Authors

MBMichael J. Burke MVMichael R. Verneris JRJennifer Le Rademacher

Discussion

Member takes

Overview

Registry study finds 48% three-year survival following hematopoietic cell transplantation in pediatric relapsed T-cell leukemia, suggesting durable efficacy after second remission.

Key Points

To assess survival, relapse, and toxicity outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with T-cell acute lymphoblastic leukemia in second complete remission.
Retrospective registry analysis of 229 pediatric patients (median age 10 years, range 2 to 18) with T-ALL in CR2 who underwent myeloablative allogeneic HCT between 2000 and 2011, reported to the CIBMTR.
Donor graft sources included matched sibling bone marrow (38%), unrelated bone marrow or peripheral blood (36%), and umbilical cord blood (26%).
Three-year overall survival was 48% (95% CI, 41% to 55%), three-year disease-free survival was 46% (95% CI, 39% to 52%), and the three-year relapse rate was 30% (95% CI, 24% to 37%).
Day-100 transplant-related mortality was 13% (95% CI, 9% to 18%), with grades II to IV acute graft-versus-host disease occurring in 35% (95% CI, 27% to 45%) and chronic GVHD in 26% (95% CI, 20% to 33%).
Prior bone marrow relapse, with or without concurrent extramedullary disease, significantly increased the risk of post-HCT relapse compared with isolated extramedullary relapse (HR, 3.94; P = .005).

Cite This Study

Burke et al. (2015) studied this question.

synapsesocial.com/papers/6a70a4f2a528af2d65c3a7f7 https://doi.org/10.1016/j.bbmt.2015.08.023

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark